Kezar Life Sciences Inc
NASDAQ:KZR 10:30:56 AM EDT
| Market Cap (Intraday) | 56.55M |
| Current PE | N/A |
| Forward PE | N/A |
| 2yr Forward PE | N/A |
| 10-Day MA | $0.71 |
| 50-Day MA | $0.61 |
| 200-Day MA | $0.76 |
Kezar Life Sciences Inc Stock, NASDAQ:KZR
4000 Shoreline Court, Suite 300, South San Francisco, California 94080
United States of America
Phone: +1.650.822.5600
Number of Employees: 58
Description
Kezar Life Sciences, Inc. is a clinical-stage biopharmaceutical company which engages in the development of novel small molecule therapeutics to treat autoimmunity and cancer. Its product pipeline includes KZR-616, KZR-261, and KZR-TBD. The company was founded by John Fowler, Christopher J. Kirk, and Jack Taunton on February 20, 2015 and is headquartered in South San Francisco, CA.